At its meeting on 2 January 2023, the Transparency Council adopted opinion No. 2/2023 on the legitimacy of granting reimbursement approvals for the medicine Fostex Nexthaler (beclometasone dipropionaate anhydricus + formoterol fumarat dihydricus) for the indications: chronic obstructive pulmonary disease; asthma.